In the longer term, as VR and brain-computer interfaces evolve, we may reach a point where we can simulate an entire meal ...

The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...

Google was a huge presence at GDC, pushing Gemini for video games and new mobile gaming tech. The one blatant no-show? Any ...

Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.

XR, a global technology company, has formed a new partnership with Scope3, which aims to decarbonize media and advertising, to integrate advanced carbon emissions data directly into XR’s platform.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...

Samsung is set to launch new XR smart glasses this year, developed under the codename Project HAEAN. These lightweight ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...

At Samsung's Galaxy Unpacked event in January, the company teased an XR headset in the vein of the Apple Vision Pro, ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...